• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Fate Therapeutics Inc.

    2/12/24 6:06:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FATE alert in real time by email
    SC 13G 1 ff3013867_13g-fate.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    Fate Therapeutics, Inc.
    (Name of Issuer)
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
    31189P102
    (CUSIP Number)
    January 31, 2024
    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





    CUSIP No. 31189P102
    13G
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Capital, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    6,171,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    6,171,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    6,171,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.3%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     




    CUSIP No. 31189P102
    13G
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Asser Management Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Bahamas
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    6,171,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    6,171,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    6,171,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.3%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     




    CUSIP No. 31189P102
    13G
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Joe Lewis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    6,171,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    6,171,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    6,171,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.3%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     




    CUSIP No. 31189P102
    13G
     

    1
    NAMES OF REPORTING PERSONS
     
     
    MVA Investors, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    290,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    290,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    290,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.3%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     




    CUSIP No. 31189P102
    13G
     

    1
    NAMES OF REPORTING PERSONS
     
     
    Aaron I. Davis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    290,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    290,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    290,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.3%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     





    Item 1. (a)
    Name of Issuer
       
      The name of the issuer is Fate Therapeutics, Inc. (the “Issuer”).
       
    Item 1. (b) Address of Issuer’s Principal Executive Offices
       
      The Issuer’s principal executive offices are located at 12278 Scripps Summit Drive, San Diego, CA 92131.
       
    Item 2. (a) Name of Person Filing
       
      This Schedule 13G is jointly filed by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”), Joe Lewis, MVA Investors, LLC (“MVA Investors”) and Aaron I. Davis (collectively, the “Reporting Persons”). Boxer Management is the managing member and majority owner of Boxer Capital. Joe Lewis is the sole indirect beneficial owner of and controls Boxer Management. MVA Investors is the independent, personal investment vehicle of certain employees of Boxer Capital. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors.
       
    Item 2. (b)
    Address of Principal Business Office or, if None, Residence
       
     
    The principal business address of Boxer Capital, MVA Investors and Aaron I. Davis is: 12860 El Camino Real, Suite 300, San Diego, CA 92130. The principal business address of Boxer Management and Joe Lewis is: Cay House, EP Taylor Drive N7776, Lyford Cay, New Providence, Bahamas.
       
     Item 2. (c)
    Citizenship
       
      Boxer Capital and MVA Investors are limited liability companies organized under the laws of Delaware. Boxer Management is a corporation organized under the laws of the Bahamas. Joe Lewis is a citizen of the United Kingdom. Aaron I. Davis is a citizen of the United States of America.
       
    Item 2. (d)
    Title of Class of Securities
       
      Common Stock, $0.001 par value per share (“Common Stock”).
       
    Item 2. (e)
    CUSIP Number
       
     
    The CUSIP number for the Common Stock is 31189P102.
       
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
       
     
    Not Applicable.
       
    Item 4.
    Ownership
       
     
    (a)
    Amount beneficially owned:





     
    Boxer Capital, Boxer Management and Joe Lewis beneficially own 6,171,000 shares of Common Stock. MVA Investors and Aaron I. Davis beneficially own 290,000 shares of Common Stock. The Reporting Persons beneficially own, in the aggregate, 6,461,000 shares of Common Stock.
     
     
    (b)
    Percent of class:
       
     
    All percentages of beneficial ownership set forth herein are based on 98,601,966 shares of Common Stock reported outstanding on October 31, 2023 in the Quarterly Report on Form 10-Q filed by the Issuer with the Securities and Exchange Commission on November 8, 2023. The number of shares of Common Stock beneficially owned by the Reporting Persons in the aggregate represent 6.6% of the Issuer’s outstanding shares of Common Stock.
       
     
    (c)
    Number of shares as to which such person has:
       
       
    (i) Sole power to vote or to direct the vote:
           
         
    None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock.
         
       
    (ii) Shared power to vote or to direct the vote:
         
         
    Boxer Capital, Boxer Management and Joe Lewis have shared power to vote or to direct the vote of 6,171,000 shares of Common Stock. MVA Investors and Aaron I. Davis have shared power to vote or to direct the vote of 290,000 shares of Common Stock.
           
       
    (iii) Sole power to dispose or to direct the disposition of:
           
         
    None of the Reporting Persons has sole power to dispose or to direct the disposition of any shares of Common Stock.
           
       
    (iv) Shared power to dispose or to direct the disposition of:
           
          Boxer Capital, Boxer Management and Joe Lewis have shared power to dispose or to direct the disposition of 6,171,000 shares of Common Stock. MVA Investors and Aaron I. Davis have shared power to dispose or to direct the disposition of 290,000 shares of Common Stock.
           
    Item 5.
    Ownership of Five Percent or Less of a Class
       
     
    Not Applicable.
       
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
       
     
    Other than as may result from indirect interests of investors in Boxer Capital and MVA Investors, no persons other than the Reporting Persons have the right to receive or the




     
    power to direct the receipt of dividends, or proceeds of sale of the securities disclosed herein.
       
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
       
     
    Not Applicable.
       
    Item 8.
    Identification and Classification of Members of the Group
       
     
    Not Applicable.
       
    Item 9.
    Notice of Dissolution of Group
       
     
    Not Applicable.
       
    Item 10.
    Certification
       
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
       
    Exhibits  
    1
    Joint Filing Agreement, dated February 12, 2024, among the Reporting Persons.





    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  February 12, 2024
     
     
    BOXER CAPITAL, LLC
     
     
     
     
     
    By:
    /s/ Aaron I. Davis
     
     
     
    Name:  
    Aaron I. Davis
     
     
    Title:
    Authorized Signatory
     
     
     
     
    BOXER ASSET MANAGEMENT INC.
     
     
     
     
     
    By:
    /s/ Paul Higgs
     
     
     
    Name: Paul Higgs
     
     
    Title:
    Director
     
     
     
     
    JOSEPH C. LEWIS
     
     
     
     
     
    /s/ Joseph C. Lewis
     
      
    Joseph C. Lewis, Individually
     
     
     
     
     
    MVA INVESTORS, LLC
     
         
     
    By:
    /s/ Aaron I. Davis
     
       
    Name:
    Aaron I. Davis
       
    Title:
    Authorized Signatory
         
     
    AARON I. DAVIS 
     
         
     
    /s/ Aaron I. Davis
     
      
    Aaron I. Davis, Individually
     





    Get the next $FATE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FATE

    DatePrice TargetRatingAnalyst
    11/18/2024Underperform → Neutral
    BofA Securities
    6/17/2024$4.00 → $6.00Neutral → Overweight
    Piper Sandler
    3/27/2023$6.00Equal Weight
    Wells Fargo
    1/24/2023$115.00 → $7.00Buy → Neutral
    H.C. Wainwright
    1/6/2023$20.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    1/6/2023$71.00 → $12.00Overweight → Neutral
    Piper Sandler
    1/6/2023Outperform → Market Perform
    Cowen
    1/6/2023$107.00 → $5.30Buy → Hold
    Stifel
    More analyst ratings

    $FATE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Lee Michael Stewart

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      5/30/25 6:55:53 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Redmile Group, Llc

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      5/30/25 6:54:05 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Xu Yuan

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      5/30/25 4:09:33 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FATE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

      SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

      5/30/25 4:30:14 PM ET
      $FATE
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

      SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced that clinical and preclinical data from the Company's off-the-shelf cell therapy product platform will be featured at the European Alliance of Associations for Rheumatology European Congress of Rheumatology (EULAR 2025), being held in Barcelona, Spain on June 11-14, 2025. The Company has been selected to provide an oral presentation featuring clinical data from its ongoing Phase 1 clinical trial of FT819

      5/28/25 5:54:14 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2025 the Company granted restricted stock units (RSUs) representing 30,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering in

      5/2/25 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FATE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      12/26/24 9:00:15 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Redmile Group, Llc disposed of $6,157,976 worth of shares (1,655,370 units at $3.72), acquired $6,157,976 worth of shares (1,655,370 units at $3.72) and bought $166,024 worth of shares (44,630 units at $3.72) (SEC Form 4)

      4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

      12/28/23 9:30:16 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FATE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fate Therapeutics upgraded by BofA Securities

      BofA Securities upgraded Fate Therapeutics from Underperform to Neutral

      11/18/24 3:46:41 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Fate Therapeutics from Neutral to Overweight and set a new price target of $6.00 from $4.00 previously

      6/17/24 7:25:36 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo resumed coverage on Fate Therapeutics with a new price target

      Wells Fargo resumed coverage of Fate Therapeutics with a rating of Equal Weight and set a new price target of $6.00

      3/27/23 8:55:35 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FATE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

      SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      11/14/24 7:50:18 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

      SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      10/25/24 9:37:07 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Fate Therapeutics Inc. (Amendment)

      SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

      3/25/24 5:15:23 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FATE
    Financials

    Live finance-specific insights

    See more

    $FATE
    Leadership Updates

    Live Leadership Updates

    See more
    • Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

      First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPS

      5/9/24 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

      SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, including a review of its FT819 and FT522 programs for autoimmune diseases being featured on the same day at the American Society of Gene and Cell Therapy 27th Annual Meeting. In order

      5/6/24 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

      CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FA

      2/26/24 4:01:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

      SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

      5/30/25 4:30:14 PM ET
      $FATE
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Announces Leadership Transition

      Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Vala

      11/29/24 1:05:00 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

      SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors effective immediately. Dr. Mozaffarian brings to the Company medical and scientific leadership in the field of immunology and autoimmunity, with over 20 years of research and industry experience in the discovery, development, and commercialization of novel small and large molecule therapeutics. "Dr. Moza

      7/31/24 8:00:00 AM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FATE
    SEC Filings

    See more
    • SEC Form S-8 filed by Fate Therapeutics Inc.

      S-8 - FATE THERAPEUTICS INC (0001434316) (Filer)

      6/4/25 4:02:02 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure

      8-K - FATE THERAPEUTICS INC (0001434316) (Filer)

      5/30/25 5:15:02 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Fate Therapeutics Inc.

      10-Q - FATE THERAPEUTICS INC (0001434316) (Filer)

      5/13/25 4:03:52 PM ET
      $FATE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care